The use of triiodothyronine during critical illness.
Journal
Current opinion in clinical nutrition and metabolic care
ISSN: 1473-6519
Titre abrégé: Curr Opin Clin Nutr Metab Care
Pays: England
ID NLM: 9804399
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
aheadofprint
Résumé
Thyroid hormone physiology changes during critical illness. Circulating concentration of triiodothyronine (T3), the active form of thyroid hormone decreases. It has long been uncertain whether this represents a pathologic change or if it is an adaptive phenomenon. Controlled clinical trials have been required to understand whether replacing and restoring serum T3 levels is therapeutic. Clinical trials of T3 have recently been proposed with some completed. These have been conducted in patients with sepsis, myocardial infarction, infants undergoing cardiac surgery, and acute respiratory distress syndrome. Of the completed trials, T3 administration restored serum concentrations, but was not accompanied by significant clinical benefit. Importantly, restoring serum T3 levels did not cause any adverse effects. If T3 is to be considered a therapeutic target in critical illness, further studies should consider the stage of disease it is administered, and whether there are other surrogate measures to assess adequacy of hormone replacement over and above serum T3 concentrations.
Identifiants
pubmed: 38170688
doi: 10.1097/MCO.0000000000001012
pii: 00075197-990000000-00131
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Maiden MJ, Torpy DJ. Thyroid hormones in critical illness. Crit Care Clin 2019; 35:375–388.
Lang S, Liu Y, Qu X, et al. Association between thyroid function and prognosis of COVID-19: a retrospective observational study. Endocr Res 2021; 46:170–177.
Gao W, Guo W, Guo Y, et al. Thyroid hormone concentrations in severely or critically ill patients with COVID-19. J Endocrinol Invest 2021; 44:1031–1040.
Deng J, Zhang S, Peng F, et al. The association between FT3 with the outcome and inflammation/coagulopathy/fibrinolysis of COVID-19. Front Endocrinol (Lausanne) 2022; 13:877010.
Llamas M, Garo ML, Giovanella L. Low free-T3 serum levels and prognosis of COVID-19: systematic review and meta-analysis. Clin Chem Lab Med 2021; 59:1906–1913.
Okoye C, Niccolai F, Rogani S, et al. Is nonthyroidal illness syndrome (NTIS) a clinical predictor of COVID-19 mortality in critically ill oldest old patients? J Endocrinol Invest 2022; 45:1689–1692.
Calcaterra V, Biganzoli G, Dilillo D, et al. Nonthyroidal illness syndrome and SARS-CoV-2-associated multisystem inflammatory syndrome in children. J Endocrinol Invest 2022; 45:199–208.
Pantos C, Kostopanagiotou G, Armaganidis A, et al. Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: a structured summary of a study protocol for a randomised controlled trial. Trials 2020; 21:573.
Mourouzis I, Apostolaki V, Trikas A, et al. The potential of thyroid hormone therapy in severe COVID-19: rationale and preliminary evidence. Int J Environ Res Public Health 2022; 19:8063.
Flory CM, Norris BJ, Larson NA, et al. A preclinical safety study of thyroid hormone instilled into the lungs of healthy rats-an investigational therapy for ARDS. J Pharmacol Exp Ther 2021; 376:74–83.
Portman MA, Slee A, Olson AK, et al. Triiodothyronine Supplementation in Infants and Children Undergoing Cardiopulmonary Bypass (TRICC): a multicenter placebo-controlled randomized trial: age analysis. Circulation 2010; 122: (Suppl): S224–S233.
Portman MA, Slee AE, Roth SJ, et al. Triiodothyronine Supplementation in Infants Undergoing Cardiopulmonary Bypass: a randomized controlled trial. Semin Thorac Cardiovasc Surg 2023; 35:105–112.
Marwali EM, Lopolisa A, Sani AA, et al. Indonesian study: triiodothyronine for infants less than 5 months undergoing cardiopulmonary bypass. Pediatr Cardiol 2022; 43:726–734.
Karri S, Mandal B, Kumar B, et al. Effect of perioperative use of oral triidothyronine for infants undergoing complex congenital cardiac surgeries under cardiopulmonary bypass: a double-blinded randomised controlled study. Ann Card Anaesth 2022; 25:270–278.
Pantos CI, Trikas AG, Pissimisis EG, et al. Effects of acute triiodothyronine treatment in patients with anterior myocardial infarction undergoing primary angioplasty: evidence from a pilot randomized clinical trial (ThyRepair Study). Thyroid 2022; 32:714–724.
Dhar R, Marklin GF, Klinkenberg WD, et al. Intravenous levothyroxine for unstable brain-dead heart donors. NEJM 2023; 389:2029–2038.